GlassScriptPhysician profile
Troy Noonan
NPI 1033112909
$22,225.90
in general payments reported to CMS, 2019-2025
37 companies · $4,671 in 2025
The $4,671 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,067 · 2020: $2,457 · 2021: $3,042 · 2022: $3,443 · 2023: $3,380 · 2024: $3,167 · 2025: $4,671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,217.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $2,061.17 | 2019-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,049.56 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,980.21 | 2019-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Abbvie INC. | $1,684.98 | 2021-2025 | |
| Tris Pharma INC | $1,275.21 | 2019-2025 | Dyanavel Xr, Onyda Xr, Quillivant |
| Lundbeck LLC | $1,150.38 | 2019-2025 | Rexulti |
| Alkermes, INC. | $1,141.76 | 2021-2025 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $1,048.57 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $934.38 | 2019-2024 | Jornay Pm |
| Validus Pharmaceuticals LLC | $792.60 | 2019-2025 | Equetro, Equetro, Raldesy |
| Takeda Pharmaceuticals U.S.A., INC. | $781.80 | 2019-2025 | Trintellix |
| Corium, LLC | $761.24 | 2021-2025 | Azstarys |
| Noven Therapeutics, LLC | $746.85 | 2020-2025 | Xelstrym, Secuado |
| Axsome Therapeutics, INC. | $665.51 | 2022-2025 | Auvelity, Sunosi |
| Bausch Health US, LLC | $592.66 | 2019-2025 | Aplenzin, Wellbutrin |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $522.23 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $510.06 | 2021-2025 | Ingrezza |
| Neos Therapeutics, LP | $490.14 | 2019-2025 | Adzenys Xr-Odt, Exxua |
| Eisai INC. | $406.53 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $394.44 | 2024-2025 | Cobenfy |
| Janssen Pharmaceuticals, INC | $379.62 | 2019-2024 | Spravato, Invega Sustenna |
| Allergan, INC. | $325.01 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $304.62 | 2020-2021 | |
| Almatica Pharma LLC | $212.73 | 2021-2025 | Loreev Xr, Gralise |
| Teva Pharmaceuticals USA, INC. | $179.25 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Idorsia Pharmaceuticals US INC | $161.72 | 2022-2025 | Quviviq, Quviviq |
| Merck Sharp & Dohme LLC | $121.56 | 2020-2022 | |
| Adlon Therapeutics L.P. | $113.95 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $100.58 | 2019 | |
| Livanova USA, INC. | $78.55 | 2020-2021 | |
| Tempus Ai, INC | $77.50 | 2024 | |
| Vertical Pharmaceuticals, LLC | $47.47 | 2019-2025 | Relexxii |
| Noven Pharmaceuticals, INC. | $42.38 | 2020-2023 | Xelstrym |
| Shire North American Group INC | $29.77 | 2019 | |
| Acadia Pharmaceuticals INC | $24.52 | 2022 | |
| Amgen INC. | $20.04 | 2022 | |
| Alfasigma USA, INC. | $16.35 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Noonan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.